Outbreak of type 2 vaccine-derived poliovirus in Nigeria: Emergence and widespread circulation in an underimmunized population

Journal of Infectious Diseases

Volumn 203, Issue 7, 2011, Pages 898-909

  Wassilak, Steven ^a   Pate, Muhammad Ali ^b   Wannemuehler, Kathleen ^a   Jenks, Julie ^a   Burns, Cara ^a   Chenoweth, Paul ^a   Abanida, Emmanuel Ade ^b   Adu, Festus ^d   Baba, Marycelin ^e   Gasasira, Alex ^c   Iber, Jane ^a   Mkanda, Pascal ^c   Williams, A J ^a   Shaw, Jing ^a   Pallansch, Mark ^a   Kew, Olen ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL PRIMARY HEALTH CARE DEVELOPMENT AGENCY   (Nigeria)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d UNIVERSITY OF IBADAN   (Nigeria)

^e UNIVERSITY OF MAIDUGURI   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; ORAL POLIOMYELITIS VACCINE; TRIPLE VACCINE;

ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG FORMULATION; EPIDEMIC; HEALTH PROGRAM; HUMAN; IMMUNIZATION; INCIDENCE; MAJOR CLINICAL STUDY; NIGERIA; POLIOMYELITIS; POLIOMYELITIS VIRUS; POLIOMYELITIS VIRUS 2; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; VIRUS ISOLATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; FEMALE; GENOME, VIRAL; HEALTH POLICY; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MUTATION; NIGERIA; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINES; VACCINATION; YOUNG ADULT;

EID: 79953012135     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq140     Document Type: Article

References (48)

1. Centers for Disease Control and Prevention. Progress toward interruption of wild poliovirus transmission - worldwide, 2009. Morbid Mortal Wkly Rep 2010; 59:545-50.
2. Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine - live. In Plotkin SA, Orenstein WA, Offit PA, eds: Vaccines, 5th ed. Philadelphia: W.B. Saunders Company, 2008; 631-85.
3. Centers for Disease Control and Prevention. Apparent global interruption of wild poliovirus type 2 transmission. Morbid Mortal Wkly Rep 2001; 50:222-4.
4. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Ann Rev Microbiol 2005; 59:587-635. (Pubitemid 41507443)
5. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses-worldwide, January 2008-June 2009. Morbid Mortal Wkly Rep 2009; 58:1002-6.
6. Minor PD, Almond JW. Poliovirus vaccines: molecular biology and immune response. In Semler BL, Wimmer E, eds: Molecular biology of Picornaviruses. Washington, DC: ASM Press, 2002; 381-90.
7. Jorba J, Campagnoli R, De L, Kew O. Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range. J Virol 2008; 82:4429-40. (Pubitemid 351563679)
8. Alexander JP Jr, Gary HE Jr, Pallansch MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J Infect Dis 1997; 175:S176-S182. (Pubitemid 27053506)
9. Estívariz C, Watkins MA, Handoko D, et al. A large vaccine-derived poliovirus outbreak on Madura Island-Indonesia, 2005. J Infect Dis 2008; 197:347-54. (Pubitemid 351263415)
10. Rakoto-Andrianarivelo M, Gumede N, Jegouic S, et al. Reemergence of recombinant vaccine-derived poliovirus outbreak in Madagascar. J Infect Dis 2008; 197:1427-35. (Pubitemid 351706467)
11. Nathanson N, Martin JR. The epidemiology of poliomyelitis: enigmas surrounding its appearance, epidemicity, and disappearance. Am J Epidemiol 1979; 110:672-92.
12. Jenkins HE, Aylward RB, Gasasira A, et al. Effectiveness of immunization against paralytic poliomyelitis in Nigeria. N Engl J Med 2008; 359:1666-74.
13. Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication-Nigeria, January 2009-July 2010. Morbid Mortal Wkly Rep 2010; 59:802-7.
14. Centers for Disease Control and Prevention. Resurgence of wild poliovirus type 1 transmission and consequences of importation-21 countries, 2002-2005. Morbid Mortal Wkly Rep 2006; 55:145-50.
15. Centers for Disease Control and Prevention. Wild poliovirus type 1 and type 3 importations - 15 countries, Africa, 2008-2009. Morbid Mortal Wkly Rep 2009; 58:357-62.
16. Adu FD, Iber J, Bukbuk D, et al. Isolation of recombinant type 2 vaccine-derived poliovirus (VDPV) from a Nigerian child. Virus Res 2007; 127:17-25. (Pubitemid 46795515)
17. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses - worldwide, January 2006-August 2007. Morbid Mortal Wkly Rep 2007; 56:996-1001.
18. Yang C-F, Naguib T, Yang S-J, et al. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt, 1983 to 1993. J Virol 2003; 77:8366-77.
19. Wringe A, Fine PEM, Sutter RW, and Kew OM. Estimating the extent of vaccine-derived poliovirus infection. PLoS ONE 2008 3:e3433.
20. Centers for Disease Control and Prevention. Laboratory surveillance for wild and vaccine-derived polioviruses-Worldwide, January 2008-June 2009. Morbid Mortal Wkly Rep 2009; 58:950-4.
21. Jenkins HE, Aylward RB, Gasasira A, et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. N Engl J Med 2010; 362:2360-9.
22. National Population Commission. Federal Republic of Nigeria. Final 2006 census results. Available at: http://www.population.gov.ng/index.php. Accessed 20 September 2010.
23. United Nations Secretariat. Population Division of the Department of Economic and Social Affairs. Nigeria population and national density. Available at: http://esa.un.org/unpp. Accessed 20 September 2010.
24. Food and Agriculture Organization of the United Nations. FAO country profiles and mapping information system. Available at: http://www.fao.org/ countryprofiles/Maps/NGA/10/pt/index.html. Accessed 20 September 2010.
25. World Bank. Health nutrition and population stats. Available at: http://ddp-ext.worldbank.org/ext/DDPQQ/member.do?method=getMembers&userid= 1&queryId=225. Accessed 20 September 2010.
26. World Health Organization. National Health Accounts: Nigeria, 2008. Available at: http://www.who.int/nha/country/nga.pdf. Accessed 20 September 2010.
27. World Health Organization and UNICEF. WHO-UNICEF estimates of immunization coverage: the Federal Republic of Nigeria, 1980-2009. Available at: http://apps.who.int/immunization-monitoring/en/globalsummary/timeseries/ TSWUcoverageByCountry.cfm?country=NGA. Accessed 20 September 2010.
28. Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication - Nigeria, January 2000-March 2002. Morbid Mortal Wkly Rep 2002; 51:479-81.
29. World Health Organization and UNICEF. Nigeria: WHO and UNICEF estimates of immunization coverage, 1997-2009. Available at: http://www.who.int/ immunization-monitoring/data/nga.pdf. Accessed 20 September 2010.
30. Measure DHS. Demographic and Health Surveys, Nigeria 2003 and 2008. Available at: http://www.measuredhs.com/aboutsurveys/dhs/start.cfm. Accessed 20 September 2010.
31. National Programme on Immunization. Report of the Federal Republic of Nigeria immunization coverage survey, 2003. Abuja, Nigeria: 2004.
32. National Programme on Immunization. Report of the Federal Republic of Nigeria immunization coverage survey, 2006. Abuja, Nigeria: 2007.
33. UNICEF. Multiple indicator cluster surveys, Nigeria 2007, Available at: http://www.childinfo.org/files/MICS3-Nigeria-FinalReport-2007-Eng.pdf. Accessed 20 September 2010.
34. World Health Organization. Field guide for supplementary activities aimed at achieving polio eradication. Geneva, Switzerland: World Health Organization, 1997; 1-153.
35. World Health Organization. Conclusions and recommendations of the Advisory Committee on Poliomyelitis Eradication, Geneva, 11-12 October 2005. Wkly Epidemiol Rec 2005; 80:410-6.
36. Oak Ridge National Laboratory. LandScan Global Population Database. Available at: http://www.ornl.gov/landscan/. Accessed 20 September 2010.
37. World Health Organization. Polio laboratory manual, 4th ed. Geneva: World Health Organization, 2004.
38. Kilpatrick DR, Nottay B, Yang C-F, et al. Group-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residues at positions of codon degeneracy. J Clin Microbiol 1996; 34:2990-6. (Pubitemid 26389346)
39. Kilpatrick DR, Nottay B, Yang C-F, et al. Serotype-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residues at positions of codon degeneracy. J Clin Microbiol 1998; 36:352-7. (Pubitemid 28060294)
40. van der Avoort HGAM, Hull BP, Hovi T, et al. A comparative study of five methods of intratypic differentiation of polioviruses. J Clin Microbiol 1995; 33:2562-6.
41. Liu H-M, Zheng D-P, Zhang L-B, Oberste MS, Pallansch MA, Kew OM. Molecular evolution of a type 1 wild-vaccine poliovirus recombinant during widespread circulation in China. J Virol 2000; 74:11153-61. (Pubitemid 32223982)
42. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2009.
43. World Health Organization. Advisory Committee on Poliomyelitis Eradication: recommendations on the use of bivalent oral poliovirus vaccine types 1 and 3. Wkly Epidemiol Rec 2009; 84:289-90.
44. Kew OM, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002; 296:356-9. (Pubitemid 34303692)
45. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991; 13:926-39.
46. World Health Organization. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol Rec 2010; 85:213-28.
47. Shimizu H, Thorley B, Paladin FJ, et al. Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001. J Virol 2004; 78:13512-21.
48. Odoom JK, Yunus Z, Dunn G, Minor PD, Martín J. Changes in population dynamics during long-term evolution of Sabin type 1 poliovirus in an immunodeficient patient. J Virol 2008; 82:9179-90.